Patents by Inventor John T. Randolph

John T. Randolph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240307382
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: June 6, 2023
    Publication date: September 19, 2024
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
  • Publication number: 20240018133
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 18, 2024
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, SeungWon Chung, Qingwei Zhang, Lei Shi, Kathleen J. Murauski, Michael J. Dart, John T. Randolph, Hanae Benelkebir
  • Publication number: 20240000792
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 4, 2024
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, SeungWon Chung, Qingwei Zhang, Lei Shi, Kathleen J. Murauski, Michael J. Dart, John T. Randolph
  • Publication number: 20230285378
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: September 9, 2022
    Publication date: September 14, 2023
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Warren M. Kati, Tammie K. Jinkerson, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Publication number: 20220354959
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 10, 2022
    Applicant: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
  • Publication number: 20220251123
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: September 2, 2021
    Publication date: August 11, 2022
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20210363136
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: April 30, 2020
    Publication date: November 25, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, SeungWon Chung, Qingwei I Zhang, Lei Shi, Kathleen J. Murauski, Michael J. Dart, John T. Randolph, Hanae Benelkebir
  • Patent number: 11149043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 19, 2021
    Assignees: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20210230195
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20210169892
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: June 10, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, SeungWon Chung, Qingwei I. Zhang, Lei Shi, Kathleen J. Murauski, Michael J. Dart, John T. Randolph
  • Publication number: 20200347043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: April 30, 2020
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Lei Shi, Kathleen J. Murauski, Xiangdong Xu, Yunsong Tong, John T. Randolph, Michael J. Dart, Hanae Benelkebir, Steven Edeson, Kathryn Starbuck
  • Publication number: 20200345727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
  • Publication number: 20200338208
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: April 16, 2020
    Publication date: October 29, 2020
    Applicant: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, JR., John T. Randolph
  • Patent number: 10668167
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: June 2, 2020
    Assignee: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
  • Publication number: 20190358214
    Abstract: The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a or a pharmaceutically acceptable salt thereof. In another embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) a prodrug of Compound 2a (e.g., one of Compounds 2b-2k or Examples 3-1 to 3-10) or a pharmaceutically acceptable salt of said prodrug.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 28, 2019
    Applicant: AbbVie Inc.
    Inventors: Brian Brown, Hui-Ju Chen, David DeGoey, Geoff Halvorsen, John Hartung, Howard R. Heyman, Nathan Ide, Dale Kempf, Allen C. Krueger, Tao Li, Tongmei Li, Steven R. Martinez, Christopher C. Marvin, John T. Randolph, Eric Voight, Rolf Wagner, Jaclyn Chau
  • Publication number: 20190262465
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Applicant: AbbVie Inc.
    Inventors: Michael J. MCPHERSON, Adrian D. HOBSON, Martin E. HAYES, Christopher C. MARVIN, Diana SCHMIDT, Wendy WAEGELL, Christian GOESS, Jason Z. OH, Axel HERNANDEZ, Jr., John T. RANDOLPH
  • Publication number: 20190015402
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 17, 2019
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Patent number: 10053474
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 21, 2018
    Assignee: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
  • Patent number: 10039754
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: August 7, 2018
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Patent number: 10028937
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 24, 2018
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller